Kiniksa files Rule 144 to sell 40,000 shares

Kiniksa Pharmaceuticals, Ltd. submitted a Rule 144 notice reporting the sale of 40,000 Class A ordinary shares on 03/02/2026.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals, Ltd. submitted a Rule 144 notice reporting the sale of 40,000 Class A ordinary shares on 03/02/2026. The transaction is described as an employee stock option exercise settled as a broker payment for a cashless exercise through Charles Schwab & Co., Inc..

Insights

Securities Compliance Counsel

Routine Rule 144 notice for a cashless option exercise; administrative disclosure.

Rule 144 filings commonly disclose restricted or control-party transactions; this entry lists 40,000 Class A ordinary shares sold on 03/02/2026 as a broker payment for a cashless exercise. The filing names Charles Schwab & Co., Inc. as the broker.

Because this is a notice of resale under Rule 144 and the filing cites an employee stock option exercise, the cash‑flow treatment is the broker payment mechanism indicated; timing and proceeds details beyond the sale date and share count are not provided in the excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does KNSA's Rule 144 filing report?

The filing reports the sale of 40,000 Class A ordinary shares by Kiniksa on 03/02/2026. It is described as an employee stock option exercise settled via a broker payment for a cashless exercise through Charles Schwab.

Who acted as broker for the transaction in the KNSA Rule 144?

The filing lists Charles Schwab & Co., Inc. as the broker handling the transaction. The broker is recorded in connection with the broker payment for a cashless exercise on 03/02/2026 for 40,000 shares.

Does the Rule 144 notice disclose proceeds or price for KNSA shares?

The excerpt identifies 40,000 shares and an amount $1,792,970.00 in the header, but it does not link a labeled net proceeds sentence to the sale. The filing describes the method as a broker cashless exercise rather than stating gross proceeds.

What is the reason given for the share sale in the KNSA filing?

The sale is attributed to an employee stock option exercise and specifically noted as a broker payment for a cashless exercise. The filing frames the transaction as option-related, not an open-market voluntary disposition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 05:22 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001741533
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc
SEC File Number	001-38492
Address of Issuer	105 PICCADILLY, SECOND FLOOR LONDON UNITED KINGDOM W1J 7NJ
Phone	7814319100
Name of Person for Whose Account the Securities are To Be Sold	Paolini John F.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Ordinary Share	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	40000	1792970.00	45900637	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Share	03/02/2026	Employee Stock Option Exercise	Kiniksa Pharmaceuticals, Ltd.			40000	03/02/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	03/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/18/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	John F. Paolini
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)